Achieve Life Sciences (ACHV) Equity Average (2011 - 2026)

Achieve Life Sciences has disclosed Equity Average across 16 years of filings, most recently posting $16.1 million for Q1 2026.

• Quarterly Equity Average rose 3.27% year-over-year to $16.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.1 million (up 3.27% YoY) and the FY2025 annual result came in at $21.2 million, up 118.07% from the prior year.
• Equity Average declined to $16.1 million in Q1 2026, from $27.6 million in the prior quarter.
• Over five years, Equity Average peaked at $45.9 million in Q2 2024 and troughed at $1.3 million in Q4 2023.
• A 5-year average of $19.2 million and a median of $17.3 million in 2022 frame the typical range for Equity Average.
• Annual changes were most pronounced in 2022 — Equity Average sank 85.1% — and 2024, when it soared 1918.42%.
• Tracing ACHV's Equity Average over 5 years: stood at $4.7 million in 2022, then sank by 72.29% to $1.3 million in 2023, then surged by 1918.42% to $26.1 million in 2024, then grew by 5.46% to $27.6 million in 2025, then sank by 41.6% to $16.1 million in 2026.
• Business Quant data shows ACHV's Equity Average at $16.1 million in Q1 2026, $27.6 million in Q4 2025, and $37.6 million in Q3 2025.